SCHEMBL1015351

SCHEMBL1015351

CC(C)(c1cc(NC(=O)Oc2ccccc2)no1)C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 8/20 0.50
MAPK11 Q15759 2/20 0.50
MAPK14 Q16539 2/20 0.50
MAPK13 O15264 1/20 0.50
MAPK12 P53778 1/20 0.50
RAB9A P51151 4/20 0.48
NPC1 O15118 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
FLT3 P36888 3/20 0.46
BRAF P15056 3/20 0.46
RIPK2 O43353 1/20 0.46
JAK2 O60674 1/20 0.46
ABL1 P00519 1/20 0.46
EGFR P00533 1/20 0.46
LCK P06239 1/20 0.46
CSF1R P07333 1/20 0.46
LYN P07948 1/20 0.46
RET P07949 1/20 0.46
MET P08581 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1015499 0.90 RAF1 (0.52) RAF1MAPK11MAPK14MAPK13MAPK12
SCHEMBL1012219 0.88 CNR2 (0.46) RAF1MAPK11MAPK14MAPK13MAPK12
SCHEMBL769541 0.87 RAF1 (0.64) RAF1MAPK11MAPK14MAPK13MAPK12
SCHEMBL4903102 0.87 RAF1 (0.48) RAF1MAPK11MAPK14MAPK13MAPK12
SCHEMBL11966207 0.84 RAF1 (0.47) RAF1MAPK11MAPK14MAPK13MAPK12
SCHEMBL1011493 0.84 RAF1 (0.49) RAF1MAPK11MAPK14MAPK13MAPK12
SCHEMBL21479385 0.84 NPC1 (0.47) RAF1MAPK11MAPK14MAPK13MAPK12
SCHEMBL769245 0.82 RAF1 (0.50) RAF1MAPK11MAPK14MAPK13MAPK12
SCHEMBL11293751 0.82 RAF1 (0.50) RAF1MAPK11MAPK14MAPK13MAPK12
SCHEMBL770045 0.82 RAF1 (0.50) RAF1MAPK11MAPK14MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240158394-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-05-16 US disclosed
WO-2024059200-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2024-03-21 WO disclosed
US-10499640-B2 Herbicidal compounds SYNGENTA PARTICIPATIONS AG (CH) 2019-12-10 US disclosed
US-10499640-B2 Herbicidal compounds SYNGENTA PARTICIPATIONS AG (CH) 2019-12-10 US disclosed
US-10053430-B2 RAF kinase modulator compounds and methods of use thereof AMBIT BIOSCIENCES CORP. (US) 2018-08-21 US disclosed
US-9987281-B2 Solid state forms of a quinazoline derivative and its use as a BRAF inhibitor IGNYTA, INC. (US) 2018-06-05 US disclosed
EP-2268623-B9 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP (US) 2018-02-28 EP disclosed
US-20170318810-A1 Herbicidal Compounds SYNGENTA PARTICIPATIONS AG (CH) 2017-11-09 US disclosed
US-20170318810-A1 Herbicidal Compounds SYNGENTA PARTICIPATIONS AG (CH) 2017-11-09 US disclosed
US-20170318810-A1 Herbicidal Compounds SYNGENTA PARTICIPATIONS AG (CH) 2017-11-09 US disclosed
US-20140045868-A1 RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2014-02-13 US disclosed
US-8618289-B2 RAF kinase modulator compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION (US) 2013-12-31 US disclosed
US-20130310357-A1 Azolyl Urea Compounds and Methods of Use Thereof AMBIT BIOSCIENCES CORPORATION (US) 2013-11-21 US disclosed
US-20130035326-A1 BIARYL COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2013-02-07 US disclosed
EP-2467137-A1 BIARYL COMPOUNDS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2012-06-27 EP disclosed
WO-2011150198-A1 AZOLYL UREA COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2011-12-01 WO disclosed
US-20110118245-A1 RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP. 2011-05-19 US disclosed
WO-2011022473-A1 BIARYL COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2011-02-24 WO disclosed
EP-2268623-A1 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2011-01-05 EP disclosed
WO-2009117080-A1 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATON (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10053430-B2 RAF kinase modulator compounds and methods of use thereof BRAF, RAF1, ARAF RAF1 2/4885MAPK11 182/4885MAPK14 145/4885
US-20110118245-A1 RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF RAF1 2/4885MAPK11 81/4885MAPK14 80/4885
US-10499640-B2 Herbicidal compounds DDT, HPD, CBR3 RAF1 1376/4885MAPK11 3737/4885MAPK14 3473/4885
US-20170318810-A1 Herbicidal Compounds DDT, HPD, CBR3 RAF1 1376/4885MAPK11 3737/4885MAPK14 3473/4885
US-20130310357-A1 Azolyl Urea Compounds and Methods of Use Thereof CSF1R, CSF3R, ARG1 RAF1 506/4885MAPK11 1292/4885MAPK14 1010/4885
US-20240158394-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 RAF1 944/4885MAPK11 685/4885MAPK14 694/4885
US-20130035326-A1 BIARYL COMPOUNDS AND METHODS OF USE THEREOF FLT3, CSF3R, CSF1R RAF1 158/4885MAPK11 2160/4885MAPK14 1534/4885
US-20140045868-A1 RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF RAF1 2/4885MAPK11 182/4885MAPK14 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.